1. Home
  2. STG vs HURA Comparison

STG vs HURA Comparison

Compare STG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STG
  • HURA
  • Stock Information
  • Founded
  • STG 2003
  • HURA 2009
  • Country
  • STG China
  • HURA United States
  • Employees
  • STG N/A
  • HURA N/A
  • Industry
  • STG Other Consumer Services
  • HURA
  • Sector
  • STG Real Estate
  • HURA
  • Exchange
  • STG Nasdaq
  • HURA Nasdaq
  • Market Cap
  • STG 112.4M
  • HURA 131.8M
  • IPO Year
  • STG 2018
  • HURA N/A
  • Fundamental
  • Price
  • STG $5.66
  • HURA $2.51
  • Analyst Decision
  • STG
  • HURA Strong Buy
  • Analyst Count
  • STG 0
  • HURA 2
  • Target Price
  • STG N/A
  • HURA $11.50
  • AVG Volume (30 Days)
  • STG 2.6K
  • HURA 178.6K
  • Earning Date
  • STG 11-20-2025
  • HURA 11-14-2025
  • Dividend Yield
  • STG N/A
  • HURA N/A
  • EPS Growth
  • STG N/A
  • HURA N/A
  • EPS
  • STG 3.59
  • HURA N/A
  • Revenue
  • STG $279,374,215.00
  • HURA N/A
  • Revenue This Year
  • STG N/A
  • HURA N/A
  • Revenue Next Year
  • STG N/A
  • HURA N/A
  • P/E Ratio
  • STG $1.57
  • HURA N/A
  • Revenue Growth
  • STG N/A
  • HURA N/A
  • 52 Week Low
  • STG $4.28
  • HURA $1.80
  • 52 Week High
  • STG $15.00
  • HURA $7.20
  • Technical
  • Relative Strength Index (RSI)
  • STG 25.52
  • HURA 51.26
  • Support Level
  • STG $6.20
  • HURA $2.40
  • Resistance Level
  • STG $6.98
  • HURA $2.58
  • Average True Range (ATR)
  • STG 0.17
  • HURA 0.11
  • MACD
  • STG -0.07
  • HURA 0.02
  • Stochastic Oscillator
  • STG 13.07
  • HURA 78.57

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: